Detection tools for prediction and identification of adverse drug reactions in older patients: a systematic review and meta-analysis

Author:

Atmaja Dewi SusantiORCID,Yulistiani ORCID,Suharjono ORCID,Zairina ElidaORCID

Abstract

AbstractTools to accurately predict and detect adverse drug reactions (ADR) in elderly patients have not been developed. We aimed to identify and evaluate reports on tools that predict and detect ADR in elderly patients (≥ 60 years). In this review, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Databases were searched until January 2022 using key terms “elderly,” “adverse drug reaction,” and “detection instruments.” Eighteen studies met the inclusion criteria, and they examined assorted interventions: STOPP/START version 1/2 (n = 10), Beers Criteria 2012 or 2015 (n = 4), Systematic Tool to Reduce Inappropriate Prescribing (STRIP) (n = 2), Tool to Reduce Inappropriate Medications (TRIM) (n = 1), Medication Risk Score (MERIS) (n = 1), Computerized alert systems (n = 1), and Norwegian General Practice-Nursing Home criteria (n = 1). The interventions affected the number of potential prescription omissions (OR, 0.50 [0.37–0.69]; p < 0.0001; four studies). No apparent reduction in the number of drug interactions within 2 months (OR, 0.84 [0.70–1.02]; p = 0.08; two studies) and mortality (OR, 0.92 [0.76–1.12]; p = 0.41; three studies) was observed. In conclusion, there is no definitive and validated assessment tool for detecting and predicting ADR in elderly patients. Thus, more research on refining existing tools or developing new ones is warranted.

Funder

Kementerian Riset, Teknologi dan Pendidikan Tinggi

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference35 articles.

1. (EMA) EMA. Guideline on good pharmacovigilance practices (GVP). Definition. 2017(United Kingdom): Annex I.

2. Food and Drug Administration Department of Health and Human Services, Chapter I. United States and America. Subchapter D—Drugs for human use. FDA. In: FDA; 2018.

3. Barclay, K., Frasetto, A., Robb, J. & Mandel, E. D. Polypharmacy in the elderly: How to reduce adverse drug events. Clin. Rev. 28, 38–44 (2018).

4. Andersen, L. V., Poulsen, B. K., Poulsen, M. H. & Krogh, M. L. Major drug interactions. In The ESC Handbook on Cardiovascular Pharmacotherapy 2nd edn 387–410 (Oxford University Press, 2019).

5. Schoenmakers, T. W., Teichert, M., Wensing, M. & de Smet, P. A. Evaluation of potentially drug-related patient-reported common symptoms assessed during clinical medication reviews: A cross-sectional observational study. Drug Saf. 40, 419–430. https://doi.org/10.1007/s40264-017-0504-7 (2017).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3